YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.
YS Biopharma Co(YS.US)：2024年Q3财报实现营收2381.5万美元，预期值为2284万美元；每股收益为-0.12美元，预期值为-0.07美元。
YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.